00:04 , Mar 9, 2019 |  BC Extra  |  Company News

Management tracks: Lundbeck hires first CBO; ICT opens U.S. office

Neurology company Lundbeck hired Keld Flintholm Jørgensen as its first CBO. Jørgensen, who will begin at H. Lundbeck A/S (CSE:LUN) April 4, is global head of strategic partnering at Roche (SWX:ROG;OTCQB:RHHBY). Innovative Cellular Therapeutics Co....
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
02:08 , Jan 6, 2016 |  BC Extra  |  Clinical News

Gilead terminates simtuzumab IPF study

Gilead Sciences Inc. (NASDAQ:GILD) said it stopped a Phase II study of simtuzumab ( GS-6624 ) to treat idiopathic pulmonary fibrosis. Gilead said a DMC recommended that the study be terminated early due to lack...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

Simtuzumab: Phase II data

A double-blind, U.S. and Russian Phase II trial in 236 patients with previously untreated advanced pancreatic cancer showed that 200 and 700 mg IV simtuzumab every 2 weeks plus Gemzar gemcitabine each missed the primary...
01:14 , Sep 18, 2014 |  BC Extra  |  Clinical News

Gilead's simtuzumab misses in pancreatic cancer

Gilead Sciences Inc. (NASDAQ:GILD) said simtuzumab ( GS-6624 ) missed the primary endpoint of progression-free survival (PFS) in a Phase II trial to treat patients with advanced pancreatic cancer. Patients received intravenous simtuzumab plus Gemzar...
07:00 , Sep 8, 2014 |  BioCentury  |  Strategy

Parsing Roche's IPF bet

InterMune Inc. 's third Phase III trial transformed it from a forgotten company with $70.3 million in 2013 sales of one Orphan product to a takeout play worth $8.3 billion to Roche . The question...
08:00 , Nov 25, 2013 |  BioCentury  |  Emerging Company Profile

Armo: Reviving IL-10

Armo Biosciences Inc. is set to emerge from stealth mode this week with a $20 million series A round and a license to a pegylated IL-10 program that was tested by Schering-Plough Corp. for autoimmune...
07:00 , May 28, 2012 |  BioCentury  |  Finance

AbbVie earlier

AbbVie earlier Early stage investor Abbott Biotech Ventures will start investing even earlier after parent company Abbott Laboratories (NYSE:ABT) splits in two, the firm's head of venture investment, Steven Kuemmerle, said at last week's C21...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

GS-6624: Phase II started

Last quarter, Gilead began a double-blind, U.S. Phase II trial to compare 200 and 700 mg GS-6624 in combination with FOLFIRI vs. FOLFIRI plus placebo in 265 patients who progressed after first-line oxaliplatin- and fluoropyrimidine-containing...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

GS-6624: Phase II started

Gilead began a double-blind, U.S. Phase II trial to compare 200 and 700 mg weekly GS-6624 plus gemcitabine vs. gemcitabine plus placebo in about 244 patients with metastatic pancreatic adenocarcinoma. Gilead acquired GS-6624 through its...